<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We generated a monoclonal antibody (mAb) 6G7, which recognizes a 220-kD antigen on selected subpopulations of <z:mpath ids='MPATH_458'>normal</z:mpath> myeloid and lymphoid cells and their malignant counterparts </plain></SENT>
<SENT sid="1" pm="."><plain>6G7 reacts with 90-95% of peripheral blood B cells, 70-80% of CD8(+) cells, 30-35% of CD4(+) cells, 20-40% of monocytes, and 20-40% of CD34(+) cells from bone marrow </plain></SENT>
<SENT sid="2" pm="."><plain>6G7 reacts with leukemic blasts in <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (14/16), adult <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (5/5), <z:e sem="disease" ids="C0023452" disease_type="Neoplastic Process" abbrv="">pediatric ALL</z:e> (5/9), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (8/8), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (7/7), and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (1/1) </plain></SENT>
<SENT sid="3" pm="."><plain>Long-term bone marrow culture of 6G7(+/-) cells showed the majority of clonogenic hematopoietic cells were in mAb 6G7 subpopulation </plain></SENT>
<SENT sid="4" pm="."><plain>An immunotoxin of 6G7 and ricin A chain was cytotoxic to 6G7(+) <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>mAb 6G7 has potential clinical applications for targeted immunotherapy of both <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>